影响认知功能的药物研发进展  

Progress in research and development of cognition related drugs

作　　者：于子茹 杜冠华 YU Zi-ru;DU Guan-hua(Beijing Key Laboratory of Drug Targets Identification and Drug Screening,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院、北京协和医学院药物研究所,北京市药物靶点研究与新药筛选重点实验室,北京100050

出　　处：《药学学报》2020年第5期781-788,共8页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81603100);药物创新重大项目(2018ZX09711001-003-005);中国医学科学院医学与健康科技创新工程(2017-I2M-1-010).

摘　　要：神经系统药物在整个药物研发中处于重要地位,其中调节认知功能的药物更是成为社会发展的迫切需求,但认知类药物临床供应严重不足且研发面临受挫。本文结合认知药理学的研究现状,对两大类认知药物进行简要概述,分别为影响正常认知功能的药物及改善认知功能障碍的药物。目前的新药研发集中在调节神经递质、靶向Aβ和Tau蛋白、神经保护及疏通血管等方面,仍需要新的研究方法及思路。本文将结合临床及在研药物,以阿尔茨海默病为主,提出并分析认知药理学发展的任务和挑战,总结认知药物研发策略,指出认知药理学的发展机遇,以期为广大科研人员提供新思路,共同促进认知药物的研发与发展。Nervous system drugs play an important role in the drug research and development, and the cognition related drug become the urgent needs of social development. However, drugs which can regulate cognitive function are seriously inadequate in clinical supply, and faced frustration in research and development process. In this paper,a brief overview of the two types of cognition related drugs(drugs affecting normal cognitive function and improving cognitive dysfunction) were discussed based on the current research status of cognitive pharmacology. The current research and development of new cognition related drugs focuses on regulating neurotransmitters, targeting Aβ and Tau proteins, neuroprotection and vascularization, and still requires new research methods and ideas. In this article,we summed up the research strategies based on the clinical and development of cognition related drugs, especially for the Alzheimer’s disease, then we put forward the task and challenge of cognitive pharmacology development.We aimed at providing new ideas for researchers to promote the development of cognitive drugs.

关 键 词：认知药理学 认知障碍 促智药 阿尔茨海默病 药物研发 

分 类 号：R965[医药卫生—药理学]